Question · asked by 1 review

Fixed‐dose combination aclidinium/formoterol vs aclidinium alone: Hospital admissions due to exacerbations: number of participants

Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with aclidinium alone (moderate certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Fixed‐dose combination aclidinium/formoterol vs aclidinium alone
Hospital admissions due to exacerbations: number of participants · people with COPD
Fixed‐dose combination aclidinium/formoterol showed no clear difference in hospital admissions due to exacerbations: number of participants compared with aclidinium alone (moderate certainty).
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) (2018) · Cochrane Headline outcomes only
OR 0.62 [0.29, 1.29]2 studies · 2156 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)
2018 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.